From the April 7 PR:
The presentation—“Brilacidin, a Host Defense Protein/Peptide Mimetic, Shows Potential as Broad Spectrum Inhibitor of Acutely Infectious Viruses”—is based on ongoing independent laboratory research being conducted by scientists at George Mason University (GMU)/National Center for Biodefense and Infectious Diseases (NCBID).
My re-iteration here: There has been no payment from IPIX to GMU for this broad-spectrum antiviral research. I also believe Dr. Narayanan, in the February GMU update video that was on YouTube and discussed at length here, mentioned this research was independent of the company.
Again, very good news for the company that GMU sees enough to continue funding research of B.
Market Data 
Markets 
AI
